A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients
Phase of Trial: Phase IV
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms CERKI
- Sponsors Novartis Pharmaceuticals
- 04 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2013 Planned End Date changed from 1 Feb 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 13 Nov 2012 Actual initiation date changed from 1 Feb 2012 to Mar 2012 as reported by ClinicalTrials.gov.